Author: Stella Samuel

Do the 2026 pharmacy reforms matter when selling a pharmacy? The short answer is yes. The reforms themselves are principally financial and industrial in nature. In the context of a pharmacy sale, however, their consequences extend into the legal risk allocation between vendor and purchaser. They can affect the information a vendor provides to a purchaser, the assumptions underlying financial projections, employee liabilities identified through due diligence, the warranties a vendor can safely give and, ultimately, who bears the risk if information provided during the transaction proves inaccurate or incomplete. Two developments are particularly relevant. 1. The June 2026 Addendum…

Most pharmacy sales usually start with strong momentum. But as the process unfolds, communication gaps can quietly create delays and frustration for everyone involved. A pharmacy sale involves purchasers, vendors, banks, landlords, regulators and advisers all working towards settlement at the same time. When information is delayed, unclear or assumptions are made rather than confirmed, momentum slows and transactions can become unnecessarily stressful. From a legal perspective, clear communication between all parties is one of the biggest factors in keeping a transaction on track and reaching settlement smoothly. Here are some practical ways both vendors and purchasers can help prevent…